FDA Approves First Therapy to Reduce Pancreatitis Risk - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves First Therapy to Reduce Pancreatitis Risk

In two placebo-controlled trials, triglyceride levels declined by up to 72% compared with placebo.

  • By

  • Kathryn Wighton

  • June 24, 2026

  • 2 min

Share

Objective:

To approve olezarsen (Tryngolza) for reducing triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Approach:
  • Clinical Trials: Two randomized, double-blind, placebo-controlled trials with 1,061 adults were conducted to evaluate the efficacy of olezarsen.
Key Findings:
  • Mean baseline triglyceride levels were 1,116 mg/dL.
  • In one trial, triglyceride levels decreased by 63% and 72% with 50-mg and 80-mg doses, respectively.
  • In the second trial, reductions were 49% and 55% with the 50-mg and 80-mg doses, respectively.
  • A pooled analysis indicated a lower incidence of acute pancreatitis in patients receiving olezarsen compared to placebo.
Interpretation:

The FDA recommends liver enzyme testing before treatment initiation and ongoing monitoring due to potential adverse reactions.

Limitations:
  • The trials primarily focused on short-term efficacy and safety.
  • Long-term effects and safety profile of olezarsen remain to be fully established.
Conclusion:

Olezarsen received Priority Review and Breakthrough Therapy designations for its indication.

Sources:

Original Source(s)

FDA Approves First Therapy to Reduce Pancreatitis Risk

  • by Kathryn Wighton

  • June 24, 2026

Related Content

Could Pregnancy Complications Predict CVD Risk?

Investigators found that adding pregnancy-related and female-specific factors modestly improved postpartum cardiovascular risk prediction compared with traditional risk factors alone.

How does IBD relate to joint infection risk?

Investigators assessed 90-day outcomes among patients with IBD who underwent elective total joint arthroplasty.

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.